



## **Mersana Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference**

December 21, 2016

**CAMBRIDGE, Mass., December 21, 2016** -- [Mersana Therapeutics, Inc.](#), today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Tuesday, January 10, 2017, at 2:30 p.m. PT.

### **About Mersana Therapeutics**

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms provide for expanded opportunities to provide meaningful clinical benefit to patients. Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.

###

### **Media Contact**

Paul Kidwell  
[paulkidwell@comcast.net](mailto:paulkidwell@comcast.net)  
617-680-1088

### **Investors Contact**

Stern Investor Relations, Inc.  
Christina Tartaglia  
[Christina@sternir.com](mailto:Christina@sternir.com)  
(212) 362-1200